Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
Sponsor: University of Miami
Terminated
Early termination due to lack of efficacy (overall response)
Other terminated trials from University of Miami
Other Head and Neck Cancer trials with similar outcome
Listed as NCT01794845, this PHASE2 trial focuses on Head and Neck Cancer and Recurrent Disease and remains terminated or withdrawn. Sponsored by University of Miami, it has been updated 8 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jul 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Feb 2017 — Jul 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Miami
For direct contact, visit the study record on ClinicalTrials.gov .